Citizens JMP lowered the firm’s price target on Kura Oncology (KURA) to $24 from $28 and keeps an Outperform rating on the shares following the Q2 update. The firm believes the shares continue to represent an attractive investment opportunity with zifto on track for approval in Q4.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology price target lowered to $27 from $29 at BofA
- Kura Oncology’s Promising Future: Strong Financials and Advancements in AML Treatment Drive Buy Rating
- Kura Oncology Advances Cancer Drug Pipeline with FDA Review
- Kura Oncology: Strong Financials and Promising Clinical Developments Drive Buy Rating
- Kura Oncology’s Promising Clinical Developments and Financial Stability Justify Buy Rating